AnaptysBio

ANAB NASDAQ
53.91
+0.97
+1.83%
After Hours: 53.91 0 0.00% 17:53 07/17 EDT
Open
52.93
Prev Close
52.94
High
54.61
Low
51.73
Volume
210.18K
Avg Vol (3M)
282.40K
52 Week High
110.00
52 Week Low
51.73
% Turnover
0.78%
Market Cap
1.46B
1D
5D
1M
3M
1Y
5Y

Company Profile

AnaptysBio, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology. The Company develops its product candidates using its antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation. Its product pipeline includes ANB020 and ANB019, which are being developed to treat severe inflammatory disorders with unmet medical need. The Company's ANB020 product candidate is an antibody that inhibits the activity of interleukin-33, and is used for the treatment of severe adult asthma and severe adult peanut allergy. In addition, the Company is engaged in developing its ANB019 product candidate, an antibody that inhibits the interleukin-36 receptor, for the treatment of rare inflammatory diseases called generalized pustular psoriasis (GPP) and palmoplantar pustular psoriasis (PPP).
MORE >

Recently

Name
Price
%Change